Items per page
Sort by

Send to:

Choose Destination

Results: 15

Cited In for PubMed (Select 19776290)


Treating medullary thyroid cancer in the age of targeted therapy.

Cabanillas ME, Hu MI, Jimenez C, Grubbs EG, Cote GJ.

Int J Endocr Oncol. 2014;1(2):203-216.


Overview and management of dermatologic events associated with targeted therapies for medullary thyroid cancer.

Lacouture ME, Ciccolini K, Kloos RT, Agulnik M.

Thyroid. 2014 Sep;24(9):1329-40. doi: 10.1089/thy.2013.0700. Epub 2014 Jul 15.


Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib.

Stjepanovic N, Capdevila J.

Biologics. 2014 Apr 10;8:129-39. doi: 10.2147/BTT.S39381. eCollection 2014. Review.


VEGF targets the tumour cell.

Goel HL, Mercurio AM.

Nat Rev Cancer. 2013 Dec;13(12):871-82. doi: 10.1038/nrc3627. Review.


Sorafenib in metastatic MTC - a case report and minireview of the literature.

Petrova M, Mihaylova Z, Fakirova A.

Int Med Case Rep J. 2010 May 27;3:55-8. Print 2010.


Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.

Fisher KE, Jani JC, Fisher SB, Foulks C, Hill CE, Weber CJ, Cohen C, Sharma J.

J Surg Res. 2013 Nov;185(1):217-24. doi: 10.1016/j.jss.2013.05.003. Epub 2013 May 23.


Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma.

Giunti S, Antonelli A, Amorosi A, Santarpia L.

Int J Endocrinol. 2013;2013:803171. doi: 10.1155/2013/803171. Epub 2013 Feb 21.


Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer.

Hart CD, De Boer RH.

Onco Targets Ther. 2013;6:1-7. doi: 10.2147/OTT.S27671. Epub 2013 Jan 3.


Vandetanib for the treatment of metastatic medullary thyroid cancer.

Degrauwe N, Sosa JA, Roman S, Deshpande HA.

Clin Med Insights Oncol. 2012;6:243-52. doi: 10.4137/CMO.S7999. Epub 2012 Jun 7.


SCF(β-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2.

Shaik S, Nucera C, Inuzuka H, Gao D, Garnaas M, Frechette G, Harris L, Wan L, Fukushima H, Husain A, Nose V, Fadda G, Sadow PM, Goessling W, North T, Lawler J, Wei W.

J Exp Med. 2012 Jul 2;209(7):1289-307. doi: 10.1084/jem.20112446. Epub 2012 Jun 18.


Role of vandetanib in the management of medullary thyroid cancer.

Brassard M, Rondeau G.

Biologics. 2012;6:59-66. doi: 10.2147/BTT.S24220. Epub 2012 Mar 8.


Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.

Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ.

J Clin Oncol. 2012 Jan 10;30(2):134-41. doi: 10.1200/JCO.2011.35.5040. Epub 2011 Oct 24. Erratum in: J Clin Oncol. 2013 Aug 20;31(24):3049.


Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches.

Harris PJ, Bible KC.

Expert Opin Investig Drugs. 2011 Oct;20(10):1357-75. doi: 10.1517/13543784.2011.614230. Review.


Medullary thyroid carcinoma: molecular signaling pathways and emerging therapies.

Gómez K, Varghese J, Jiménez C.

J Thyroid Res. 2011;2011:815826. doi: 10.4061/2011/815826. Epub 2011 May 16.


Activated leukocyte cell adhesion molecule expression and shedding in thyroid tumors.

Miccichè F, Da Riva L, Fabbi M, Pilotti S, Mondellini P, Ferrini S, Canevari S, Pierotti MA, Bongarzone I.

PLoS One. 2011 Feb 22;6(2):e17141. doi: 10.1371/journal.pone.0017141.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk